EP1608970A4 - Ccn3 compositions and methods - Google Patents

Ccn3 compositions and methods

Info

Publication number
EP1608970A4
EP1608970A4 EP04758632A EP04758632A EP1608970A4 EP 1608970 A4 EP1608970 A4 EP 1608970A4 EP 04758632 A EP04758632 A EP 04758632A EP 04758632 A EP04758632 A EP 04758632A EP 1608970 A4 EP1608970 A4 EP 1608970A4
Authority
EP
European Patent Office
Prior art keywords
ccn3
compositions
methods
ccn3 compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04758632A
Other languages
German (de)
French (fr)
Other versions
EP1608970A2 (en
Inventor
Lester F Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Munin Corp
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Publication of EP1608970A2 publication Critical patent/EP1608970A2/en
Publication of EP1608970A4 publication Critical patent/EP1608970A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
EP04758632A 2003-03-31 2004-03-31 Ccn3 compositions and methods Withdrawn EP1608970A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45936103P 2003-03-31 2003-03-31
US459361P 2003-03-31
PCT/US2004/009810 WO2004090109A2 (en) 2003-03-31 2004-03-31 Ccn3 compositions and methods

Publications (2)

Publication Number Publication Date
EP1608970A2 EP1608970A2 (en) 2005-12-28
EP1608970A4 true EP1608970A4 (en) 2006-06-14

Family

ID=33159647

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04758632A Withdrawn EP1608970A4 (en) 2003-03-31 2004-03-31 Ccn3 compositions and methods

Country Status (2)

Country Link
EP (1) EP1608970A4 (en)
WO (1) WO2004090109A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780949B2 (en) 2005-01-10 2010-08-24 Rosalind Franklin University Of Medicine And Science Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
DE602006021534D1 (en) * 2005-01-10 2011-06-09 Univ Rosalind Franklin Medicine & Science CCN3 proteins for the treatment and diagnosis of kidney disease
GB0618748D0 (en) * 2006-09-22 2006-11-01 Univ Belfast Peptide
US9114112B2 (en) 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
JP5939584B2 (en) 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス Therapeutic CCN3 peptides and analogs thereof
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033995A2 (en) * 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
WO2001055210A2 (en) * 2000-01-31 2001-08-02 Munin Corporation Human cyr61

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033995A2 (en) * 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
WO2001055210A2 (en) * 2000-01-31 2001-08-02 Munin Corporation Human cyr61

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ELLIS ET AL: "Nov gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, XX, XX, vol. 20, no. 8, 2000, pages 1912 - 1919, XP002987250, ISSN: 1079-5642 *
GUPTA N ET AL: "INHIBITION OF GLIOMA CELL GROWTH AND TUMORIGENIC POTENTIAL BY CCN3 (NOV)", MP. MOLECULAR PATHOLOGY, BMJ PUBLISHING GROUP, LONDON, GB, vol. 54, no. 5, October 2001 (2001-10-01), pages 293 - 299, XP008010748, ISSN: 1366-8714 *
LAU L F ET AL: "The CCN family of angiogenic regulators: the integrin connection", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 248, 1999, pages 44 - 57, XP002272896, ISSN: 0014-4827 *
LIN C G ET AL: "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 26, 27 June 2003 (2003-06-27), pages 24200 - 24208, XP002272895, ISSN: 0021-9258 *
SAKAMOTO K. ET AL.: "The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differenciation via Notch signaling pathway", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 33, 16 August 2002 (2002-08-16), pages 29399 - 29405, XP002377827 *
See also references of WO2004090109A2 *

Also Published As

Publication number Publication date
WO2004090109A2 (en) 2004-10-21
EP1608970A2 (en) 2005-12-28
WO2004090109A3 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) Methods and compositions
ZA200602885B (en) Antimicrobial compositions and methods
EP1692131A4 (en) Methods and compositions for slowing aging
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
EP1619947A4 (en) Antibacterial methods and compositions
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
HK1090639A1 (en) Immunosuppressant compounds and compositions
HK1087929A1 (en) Immunosuppressant compounds and compositions
EP1644367A4 (en) Immunosuppressant compounds and compositions
HK1095743A1 (en) Ccn1 compositions and methods ccn1
AU2003256805A8 (en) Compounds compositions and methods
EP1778219A4 (en) Ascophyllum compositions and methods
EP1613352A4 (en) Micro-cluster compositions
HRP20140660T1 (en) Compositions and uses therof
EP1608970A4 (en) Ccn3 compositions and methods
GB0300602D0 (en) Compositions
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0316857D0 (en) Compositions
GB0330062D0 (en) Compositions and methods
GB0313059D0 (en) Compositions and method
GB0321541D0 (en) Skincare compositions and methods
IL174992A0 (en) Compositions and methods including same useful for anastmosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051020

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060517

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061010

17Q First examination report despatched

Effective date: 20061010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111001